| AGAP2 |
ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 |
|
|
|
| AGO2 |
argonaute RISC catalytic component 2 |
- Pre-NOTCH Transcription and Translation
- MicroRNA (miRNA) biogenesis
- Ca2+ pathway
- Small interfering RNA (siRNA) biogenesis
- Post-transcriptional silencing by small RNAs
- Transcriptional regulation by small RNAs
- TP53 Regulates Metabolic Genes
- MAPK6/MAPK4 signaling
- Regulation of RUNX1 Expression and Activity
- Regulation of PTEN mRNA translation
- Competing endogenous RNAs (ceRNAs) regulate PTEN translation
- Transcriptional Regulation by MECP2
- Transcriptional Regulation by MECP2
- Estrogen-dependent gene expression
- Regulation of MECP2 expression and activity
- NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
|
|
|
| APP |
amyloid beta precursor protein |
- Platelet degranulation
- ECM proteoglycans
- Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
- G alpha (q) signalling events
- G alpha (i) signalling events
- Lysosome Vesicle Biogenesis
- Formyl peptide receptors bind formyl peptides and many other ligands
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- The NLRP3 inflammasome
- Advanced glycosylation endproduct receptor signaling
- Advanced glycosylation endproduct receptor signaling
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
- Post-translational protein phosphorylation
- TRAF6 mediated NF-kB activation
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
- Purinergic signaling in leishmaniasis infection
- Amyloid fiber formation
|
- Deferoxamine
- Aluminium
- Zinc
- L-methionine (R)-S-oxide
- Resveratrol
- Phenserine
- Tiomolibdate ion
- CAD106
- Mito-4509
- Dimercaprol
- Copper
- Florbetaben (18F)
- Florbetapir (18F)
- Flutemetamol (18F)
|
|
| ATG9A |
autophagy related 9A |
|
|
|
| AVIL |
advillin |
|
|
|
| AZI2 |
5-azacytidine induced 2 |
|
|
|
| CALCOCO2 |
calcium binding and coiled-coil domain 2 |
|
|
|
| CDC37 |
cell division cycle 37, HSP90 cochaperone |
- Signaling by ERBB2
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Constitutive Signaling by EGFRvIII
- Downregulation of ERBB2 signaling
- Constitutive Signaling by Overexpressed ERBB2
- Drug-mediated inhibition of ERBB2 signaling
- Signaling by ERBB2 KD Mutants
- Resistance of ERBB2 KD mutants to trastuzumab
- Resistance of ERBB2 KD mutants to sapitinib
- Resistance of ERBB2 KD mutants to tesevatinib
- Resistance of ERBB2 KD mutants to neratinib
- Resistance of ERBB2 KD mutants to osimertinib
- Resistance of ERBB2 KD mutants to afatinib
- Resistance of ERBB2 KD mutants to AEE788
- Resistance of ERBB2 KD mutants to lapatinib
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Drug resistance in ERBB2 TMD/JMD mutants
|
|
|
| CDC42BPG |
CDC42 binding protein kinase gamma |
|
|
|
| CYLD |
CYLD lysine 63 deubiquitinase |
- NOD1/2 Signaling Pathway
- TNFR1-induced proapoptotic signaling
- Regulation of TNFR1 signaling
- TNFR1-induced NFkappaB signaling pathway
- Ub-specific processing proteases
- Negative regulators of DDX58/IFIH1 signaling
|
|
- Familial cylindromatosis
- Multiple familial trichoepithelioma
- Brooke-Spiegler syndrome
|
| HSP90AA1 |
heat shock protein 90 alpha family class A member 1 |
- Signaling by ERBB2
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- vRNP Assembly
- Regulation of actin dynamics for phagocytic cup formation
- eNOS activation
- Regulation of PLK1 Activity at G2/M Transition
- Scavenging by Class F Receptors
- Scavenging by Class F Receptors
- HSP90 chaperone cycle for steroid hormone receptors (SHR)
- HSF1 activation
- Attenuation phase
- HSF1-dependent transactivation
- Loss of Nlp from mitotic centrosomes
- Recruitment of mitotic centrosome proteins and complexes
- Loss of proteins required for interphase microtubule organization from the centrosome
- Recruitment of NuMA to mitotic centrosomes
- Sema3A PAK dependent Axon repulsion
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- VEGFR2 mediated vascular permeability
- Uptake and function of diphtheria toxin
- PIWI-interacting RNA (piRNA) biogenesis
- Anchoring of the basal body to the plasma membrane
- Constitutive Signaling by EGFRvIII
- Interleukin-4 and Interleukin-13 signaling
- Neutrophil degranulation
- The role of GTSE1 in G2/M progression after G2 checkpoint
- AURKA Activation by TPX2
- Downregulation of ERBB2 signaling
- ESR-mediated signaling
- Extra-nuclear estrogen signaling
- Estrogen-dependent gene expression
- Chaperone Mediated Autophagy
- Constitutive Signaling by Overexpressed ERBB2
- Aggrephagy
- Drug-mediated inhibition of ERBB2 signaling
- Signaling by ERBB2 KD Mutants
- Resistance of ERBB2 KD mutants to trastuzumab
- Resistance of ERBB2 KD mutants to sapitinib
- Resistance of ERBB2 KD mutants to tesevatinib
- Resistance of ERBB2 KD mutants to neratinib
- Resistance of ERBB2 KD mutants to osimertinib
- Resistance of ERBB2 KD mutants to afatinib
- Resistance of ERBB2 KD mutants to AEE788
- Resistance of ERBB2 KD mutants to lapatinib
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Drug resistance in ERBB2 TMD/JMD mutants
|
- Rifabutin
- Nedocromil
- 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine
- Geldanamycin
- 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
- 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine
- 4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid
- 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
- 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine
- 9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine
- 4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole
- 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine
- 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine
- 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
- Quercetin
- 8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine
- 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
- N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
- Tanespimycin
- SNX-5422
- N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
- 4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE
- 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE
- 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
- 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
- (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one
- 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE
- 3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE
- N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE
- 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol
- 4-[4-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-3-METHYL-1H-PYRAZOL-5-YL]-6-ETHYLBENZENE-1,3-DIOL
- 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol
- 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE
- 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine
- (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime
- 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-
- 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol
- 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol
- 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide
- 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine
- 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine
- 3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE
- 2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE
- Copper
- Alvespimycin
|
|
| HSP90AB1 |
heat shock protein 90 alpha family class B member 1 |
- Regulation of actin dynamics for phagocytic cup formation
- HSP90 chaperone cycle for steroid hormone receptors (SHR)
- HSF1 activation
- Attenuation phase
- HSF1-dependent transactivation
- Sema3A PAK dependent Axon repulsion
- Uptake and function of diphtheria toxin
- Neutrophil degranulation
- The NLRP3 inflammasome
- The role of GTSE1 in G2/M progression after G2 checkpoint
- Aryl hydrocarbon receptor signalling
- ESR-mediated signaling
- Estrogen-dependent gene expression
- Chaperone Mediated Autophagy
- Purinergic signaling in leishmaniasis infection
|
- Geldanamycin
- 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine
- Radicicol
- Tanespimycin
- SNX-5422
- 4-[4-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-3-METHYL-1H-PYRAZOL-5-YL]-6-ETHYLBENZENE-1,3-DIOL
- 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE
- 4-{4-[4-(3-AMINOPROPOXY)PHENYL]-1H-PYRAZOL-5-YL}-6-CHLOROBENZENE-1,3-DIOL
- (5E)-14-CHLORO-15,17-DIHYDROXY-4,7,8,9,10,11-HEXAHYDRO-2-BENZOXACYCLOPENTADECINE-1,12(3H,13H)-DIONE
- (5Z)-12-CHLORO-13,15-DIHYDROXY-4,7,8,9-TETRAHYDRO-2-BENZOXACYCLOTRIDECINE-1,10(3H,11H)-DIONE
- (5E)-12-CHLORO-13,15-DIHYDROXY-4,7,8,9-TETRAHYDRO-2-BENZOXACYCLOTRIDECINE-1,10(3H,11H)-DIONE
- (5Z)-13-CHLORO-14,16-DIHYDROXY-3,4,7,8,9,10-HEXAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,11(12H)-DIONE
- METHYL 3-CHLORO-2-{3-[(2,5-DIHYDROXY-4-METHOXYPHENYL)AMINO]-3-OXOPROPYL}-4,6-DIHYDROXYBENZOATE
- 2-(3-AMINO-2,5,6-TRIMETHOXYPHENYL)ETHYL 5-CHLORO-2,4-DIHYDROXYBENZOATE
|
|
| IKBKB |
inhibitor of nuclear factor kappa B kinase subunit beta |
- Activation of NF-kappaB in B cells
- Activation of NF-kappaB in B cells
- ER-Phagosome pathway
- NOD1/2 Signaling Pathway
- TICAM1, RIP1-mediated IKK complex recruitment
- RIP-mediated NFkB activation via ZBP1
- Downstream TCR signaling
- p75NTR recruits signalling complexes
- NF-kB is activated and signals survival
- FCERI mediated NF-kB activation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Regulation of TNFR1 signaling
- TNFR1-induced NFkappaB signaling pathway
- IKBKB deficiency causes SCID
- IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
- IkBA variant leads to EDA-ID
- CLEC7A (Dectin-1) signaling
- MAP3K8 (TPL2)-dependent MAPK1/3 activation
- Interleukin-1 signaling
- TRAF6 mediated NF-kB activation
- NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
- IRAK1 recruits IKK complex
- IKK complex recruitment mediated by RIP1
- IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
|
- Mesalazine
- Sulfasalazine
- Acetylsalicylic acid
- Auranofin
- Arsenic trioxide
- MLN0415
- Acetylcysteine
|
|
| IKBKG |
inhibitor of nuclear factor kappa B kinase regulatory subunit gamma |
- Activation of NF-kappaB in B cells
- Activation of NF-kappaB in B cells
- ER-Phagosome pathway
- NOD1/2 Signaling Pathway
- TICAM1, RIP1-mediated IKK complex recruitment
- RIP-mediated NFkB activation via ZBP1
- Downstream TCR signaling
- FCERI mediated NF-kB activation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- activated TAK1 mediates p38 MAPK activation
- JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
- SUMOylation of immune response proteins
- Regulation of TNFR1 signaling
- TNFR1-induced NFkappaB signaling pathway
- IKBKB deficiency causes SCID
- IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
- IkBA variant leads to EDA-ID
- CLEC7A (Dectin-1) signaling
- MAP3K8 (TPL2)-dependent MAPK1/3 activation
- Ub-specific processing proteases
- Ovarian tumor domain proteases
- Interleukin-1 signaling
- TRAF6 mediated NF-kB activation
- NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
- IRAK1 recruits IKK complex
- IKK complex recruitment mediated by RIP1
- IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
|
|
- Ectodermal dysplasia associated immunodeficiency (EDA-ID), including the following two diseases: NF-kappa-B essential modulator (NEMO) defect; Inhibitor of kappa-B (I-kappa-B) defect
- Incontinentia pigmenti
- Osteoporosis, lymphedema, anhydrotic ectodermal dysplasia with immunodeficiency (OLEDAID); Ectodermal dysplasia, anhidrotic, with immunodeficiency, osteopetrosis, and lymphedema
|
| IRF3 |
interferon regulatory factor 3 |
- ISG15 antiviral mechanism
- IRF3 mediated activation of type 1 IFN
- IRF3 mediated activation of type 1 IFN
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- Regulation of innate immune responses to cytosolic DNA
- IRF3-mediated induction of type I IFN
- Interferon gamma signaling
- TICAM1-dependent activation of IRF3/IRF7
- Interferon alpha/beta signaling
- TRAF3-dependent IRF activation pathway
- TRAF6 mediated IRF7 activation
- Negative regulators of DDX58/IFIH1 signaling
- Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
|
|
|
| IRF5 |
interferon regulatory factor 5 |
- Interferon gamma signaling
- Interferon alpha/beta signaling
|
|
|
| IRF7 |
interferon regulatory factor 7 |
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Interferon gamma signaling
- TICAM1-dependent activation of IRF3/IRF7
- Interferon alpha/beta signaling
- TRAF3-dependent IRF activation pathway
- TRAF6 mediated IRF7 activation
- Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
- TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling
|
|
|
| MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
- Macroautophagy
- Pink/Parkin Mediated Mitophagy
- TBC/RABGAPs
- Receptor Mediated Mitophagy
- Pexophagy
|
|
|
| MARCHF9 |
membrane associated ring-CH-type finger 9 |
|
|
|
| MAVS |
mitochondrial antiviral signaling protein |
- DDX58/IFIH1-mediated induction of interferon-alpha/beta
- Ovarian tumor domain proteases
- TRAF3-dependent IRF activation pathway
- TRAF6 mediated IRF7 activation
- TRAF6 mediated NF-kB activation
- TRAF6 mediated NF-kB activation
- NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
- Negative regulators of DDX58/IFIH1 signaling
- Negative regulators of DDX58/IFIH1 signaling
|
|
|
| MBP |
myelin basic protein |
- EGR2 and SOX10-mediated initiation of Schwann cell myelination
|
|
|
| MIB1 |
mindbomb E3 ubiquitin protein ligase 1 |
- Activated NOTCH1 Transmits Signal to the Nucleus
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- NOTCH2 Activation and Transmission of Signal to the Nucleus
- NOTCH3 Activation and Transmission of Signal to the Nucleus
|
|
|
| MIB2 |
mindbomb E3 ubiquitin protein ligase 2 |
- Activated NOTCH1 Transmits Signal to the Nucleus
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- NOTCH2 Activation and Transmission of Signal to the Nucleus
- NOTCH3 Activation and Transmission of Signal to the Nucleus
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
| MPP3 |
membrane palmitoylated protein 3 |
|
|
|
| MTPAP |
mitochondrial poly(A) polymerase |
|
|
|
| NCK1 |
NCK adaptor protein 1 |
- Downstream signal transduction
- Generation of second messenger molecules
- Regulation of actin dynamics for phagocytic cup formation
- Regulation of actin dynamics for phagocytic cup formation
- Nephrin family interactions
- DCC mediated attractive signaling
- DCC mediated attractive signaling
- Activation of RAC1
- VEGFA-VEGFR2 Pathway
- RHO GTPases Activate WASPs and WAVEs
- RHO GTPases Activate WASPs and WAVEs
- FCGR3A-mediated phagocytosis
- FCGR3A-mediated phagocytosis
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
|
|
| NEDD4 |
NEDD4 E3 ubiquitin protein ligase |
- ISG15 antiviral mechanism
- Downregulation of ERBB4 signaling
- Regulation of PTEN localization
- Regulation of PTEN stability and activity
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
| NFKBIA |
NFKB inhibitor alpha |
- Activation of NF-kappaB in B cells
- RIP-mediated NFkB activation via ZBP1
- Downstream TCR signaling
- NF-kB is activated and signals survival
- FCERI mediated NF-kB activation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- SUMOylation of immune response proteins
- IkBA variant leads to EDA-ID
- CLEC7A (Dectin-1) signaling
- Ub-specific processing proteases
- Interleukin-1 signaling
- TRAF6 mediated NF-kB activation
|
- Acetylsalicylic acid
- Astaxanthin
|
- Ectodermal dysplasia associated immunodeficiency (EDA-ID), including the following two diseases: NF-kappa-B essential modulator (NEMO) defect; Inhibitor of kappa-B (I-kappa-B) defect
- Hodgkin lymphoma
|
| PROS1 |
protein S |
- Platelet degranulation
- Intrinsic Pathway of Fibrin Clot Formation
- Common Pathway of Fibrin Clot Formation
- Gamma-carboxylation of protein precursors
- Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus
- Removal of aminoterminal propeptides from gamma-carboxylated proteins
- Cell surface interactions at the vascular wall
- Regulation of Complement cascade
|
- Drotrecogin alfa
- Menadione
- Sodium Tetradecyl Sulfate
|
|
| PTPRD |
protein tyrosine phosphatase receptor type D |
- Receptor-type tyrosine-protein phosphatases
- Synaptic adhesion-like molecules
|
|
|
| RELA |
RELA proto-oncogene, NF-kB subunit |
- Activation of NF-kappaB in B cells
- RIP-mediated NFkB activation via ZBP1
- Regulated proteolysis of p75NTR
- Downstream TCR signaling
- NF-kB is activated and signals survival
- Senescence-Associated Secretory Phenotype (SASP)
- FCERI mediated NF-kB activation
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- PKMTs methylate histone lysines
- Transcriptional regulation of white adipocyte differentiation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Interleukin-1 processing
- SUMOylation of immune response proteins
- IkBA variant leads to EDA-ID
- Dectin-1 mediated noncanonical NF-kB signaling
- CLEC7A (Dectin-1) signaling
- CD209 (DC-SIGN) signaling
- CLEC7A/inflammasome pathway
- The NLRP3 inflammasome
- Transcriptional Regulation by VENTX
- Interleukin-1 signaling
- TRAF6 mediated NF-kB activation
- Purinergic signaling in leishmaniasis infection
|
|
|
| RIPK1 |
receptor interacting serine/threonine kinase 1 |
- Caspase activation via Death Receptors in the presence of ligand
- TICAM1, RIP1-mediated IKK complex recruitment
- RIP-mediated NFkB activation via ZBP1
- TRIF-mediated programmed cell death
- TRP channels
- Regulation by c-FLIP
- RIPK1-mediated regulated necrosis
- CASP8 activity is inhibited
- TNFR1-induced proapoptotic signaling
- Regulation of TNFR1 signaling
- TNFR1-induced NFkappaB signaling pathway
- Regulation of necroptotic cell death
- Ub-specific processing proteases
- Ovarian tumor domain proteases
- Dimerization of procaspase-8
- TNF signaling
- TLR3-mediated TICAM1-dependent programmed cell death
- NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
- IKK complex recruitment mediated by RIP1
|
|
|
| RNF128 |
ring finger protein 128 |
- Ub-specific processing proteases
- Ovarian tumor domain proteases
|
|
|
| RPS6KB1 |
ribosomal protein S6 kinase B1 |
- mTORC1-mediated signalling
|
|
|
| SCN7A |
sodium voltage-gated channel alpha subunit 7 |
- Interaction between L1 and Ankyrins
- Phase 0 - rapid depolarisation
|
- Valproic Acid
- Brivaracetam
|
|
| SIKE1 |
suppressor of IKBKE 1 |
- TRAF3-dependent IRF activation pathway
- TRAF6 mediated IRF7 activation
|
|
|
| SMCR8 |
SMCR8-C9orf72 complex subunit |
|
|
|
| SMURF1 |
SMAD specific E3 ubiquitin protein ligase 1 |
- Signaling by BMP
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- Asymmetric localization of PCP proteins
- Hedgehog 'on' state
- Hedgehog 'on' state
- Regulation of RUNX2 expression and activity
- Regulation of RUNX2 expression and activity
- Regulation of RUNX3 expression and activity
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
| SOCS2 |
suppressor of cytokine signaling 2 |
- Interleukin-7 signaling
- Neddylation
- Growth hormone receptor signaling
|
|
|
| SQSTM1 |
sequestosome 1 |
- NRIF signals cell death from the nucleus
- p75NTR recruits signalling complexes
- NF-kB is activated and signals survival
- Pink/Parkin Mediated Mitophagy
- Interleukin-1 signaling
- Pexophagy
|
|
- Paget's disease of bone and related disorders, including: ; Paget's disease of bone (PDB); Familial expansile osteolysis (FEO); Early-onset Paget's disease of bone (PDB2); Expansile skeletal hyperphosphatasia (ESH); Juvenile Paget's disease (JPD)
|
| STX11 |
syntaxin 11 |
|
|
- Familial hemophagocytic lymphohistiocytosis (FHPL), including the following three diseases: Perforin deficiency; Munc deficiency; STX11 deficiency
|
| TANK |
TRAF family member associated NFKB activator |
- TICAM1-dependent activation of IRF3/IRF7
- TRAF6 mediated IRF7 activation
- Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
|
|
|
| TICAM1 |
toll like receptor adaptor molecule 1 |
- Caspase activation via Death Receptors in the presence of ligand
- MyD88-independent TLR4 cascade
- Toll Like Receptor 3 (TLR3) Cascade
- TICAM1, RIP1-mediated IKK complex recruitment
- RIP-mediated NFkB activation via ZBP1
- TRIF-mediated programmed cell death
- TICAM1 deficiency - HSE
- TRAF3 deficiency - HSE
- TLR3-mediated TICAM1-dependent programmed cell death
- TICAM1-dependent activation of IRF3/IRF7
- TICAM1,TRAF6-dependent induction of TAK1 complex
- Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
- IKK complex recruitment mediated by RIP1
- TRAF6-mediated induction of TAK1 complex within TLR4 complex
- IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
|
|
|
| TRAF2 |
TNF receptor associated factor 2 |
- Caspase activation via Death Receptors in the presence of ligand
- Regulation by c-FLIP
- RIPK1-mediated regulated necrosis
- CASP8 activity is inhibited
- TNFR1-induced proapoptotic signaling
- Regulation of TNFR1 signaling
- TNFR1-induced NFkappaB signaling pathway
- TNFR2 non-canonical NF-kB pathway
- Regulation of necroptotic cell death
- TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
- Ub-specific processing proteases
- Dimerization of procaspase-8
- TNF signaling
- TRAF6 mediated IRF7 activation
- TRAF6 mediated NF-kB activation
- TRAF6 mediated NF-kB activation
|
|
|
| TRAF3 |
TNF receptor associated factor 3 |
- TRAF3 deficiency - HSE
- TNFR2 non-canonical NF-kB pathway
- TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
- Ovarian tumor domain proteases
- TICAM1-dependent activation of IRF3/IRF7
- TRAF3-dependent IRF activation pathway
- Negative regulators of DDX58/IFIH1 signaling
- Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
|
|
|
| TRAF3IP2 |
TRAF3 interacting protein 2 |
|
|
|
| TRAF5 |
TNF receptor associated factor 5 |
|
|
|
| TRIM21 |
tripartite motif containing 21 |
- STING mediated induction of host immune responses
- Regulation of innate immune responses to cytosolic DNA
- Interferon gamma signaling
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
| TRIM27 |
tripartite motif containing 27 |
- SUMOylation of ubiquitinylation proteins
- Regulation of PTEN stability and activity
- Suppression of apoptosis
|
|
|
| TXLNG |
taxilin gamma |
|
|
|
| XIAP |
X-linked inhibitor of apoptosis |
- Activation of caspases through apoptosome-mediated cleavage
- SMAC (DIABLO) binds to IAPs
- SMAC (DIABLO) binds to IAPs
- SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes
- SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes
- SMAC, XIAP-regulated apoptotic response
- Deactivation of the beta-catenin transactivating complex
- RIPK1-mediated regulated necrosis
- Regulation of TNFR1 signaling
- TNFR1-induced NFkappaB signaling pathway
- Regulation of necroptotic cell death
- Regulation of PTEN localization
- Regulation of PTEN stability and activity
- Regulation of the apoptosome activity
|
- 1-[3,3-Dimethyl-2-(2-Methylamino-Propionylamino)-Butyryl]-Pyrrolidine-2-Carboxylic Acid(1,2,3,4-Tetrahydro-Naphthalen-1-Yl)-Amide
- Dequalinium
- N-METHYLALANYL-3-METHYLVALYL-4-PHENOXY-N-(1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)PROLINAMIDE
|
- Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
|
| YAF2 |
YY1 associated factor 2 |
- RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
- Transcriptional Regulation by E2F6
|
|
|